Genesis AEC Identifies Power Infrastructure Risks Before Facility Acquisitions and Expansions

November 15, 2026

Genesis AEC, a leader in full-service AEC solutions for life sciences, helps owners and developers of facilities and campuses identify power and infrastructure constraints before they commit capital to an acquisition or expansion. Through its Critical Infrastructure team, Genesis provides technical due diligence, Utility Master Planning and Infrastructure Condition Evaluations to assess whether a property can support planned operations, what improvements may be required and how development can be phased around available capacity.


A utility connection or nearby substation does not establish whether a property can accommodate its intended use. Required electrical capacity may be unavailable, delayed or prohibitively expensive to obtain, creating risks of redesign, stranded capital and delayed operations. Genesis works closely with utility providers to assess whether existing infrastructure can realistically support proposed load growth and required service reliability.


Evaluations examine available feeder and transformer capacity, substation loading and redundancy, transmission constraints, utility capital improvement plans and potential cost-sharing obligations for system upgrades. This helps owners understand infrastructure limitations, potential upgrade requirements and their implications for project costs and schedules.


In one campus assessment, Genesis helped a client establish a realistic future load profile using historical data from completed projects with similar space and building types. The analysis showed how existing infrastructure could support an initial phase while the utility completed substation and feeder upgrades, a process expected to take several years. Genesis developed a phased upgrade approach that allowed part of the campus to be energized and placed into full operation before the utility upgrades were complete, with the upgraded electrical infrastructure engineered to support full campus capacity once the utility work was finished.


Genesis supports greenfield developments and existing facility and campus expansions, evaluating utility infrastructure, electrical capacity and site requirements against the owner’s intended full buildout. For existing facilities, assessments consider equipment capacity, cooling, distribution pathways, structural conditions and operational constraints. Strategic white space planning identifies where infrastructure can support additional usable space and phased growth, and where upgrades may be required. Together, these evaluations help owners compare expansion of an existing property with development of a new purpose-built critical facility.


Genesis helps owners evaluate opportunities to phase development around available electrical capacity while planning for required utility upgrades. The team evaluates the technical feasibility, operational implications and potential return on investment of “bring your own power” strategies, including on-site microgrids, battery energy storage systems, natural gas generation and hybrid utility-generation configurations.


For more information, read Genesis AEC’s blog, “The Energy Audit Before Acquisition: Why Power Infrastructure Now Defines Facility and Campus Site Value,” here.


###


About Genesis AEC

Genesis AEC, ranked as one of the top 10 firms nationwide in Pharmaceutical Design by Engineering News-Record (ENR), delivers fully integrated facility solutions for life sciences. These services span master planning, architecture and engineering, construction management, commissioning, qualification and validation (CQV), sustainability, and asset management. Backed by 30 years of experience, the firm partners with clients across the full facility lifecycle, from early strategy through long-term performance optimization. Combining global capabilities with boutique agility, Genesis AEC operates as a science-first extension of its clients’ teams, helping both emerging companies and established industry leaders accelerate the delivery of life-saving therapies.